Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Joseph Gligorov et al.|Annals of Oncology|2021Cited by 724
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized TrialsSabino De Placido, Giuseppe Cancello, Diego D’Agostino et al.|Journal of Clinical Oncology|2007Cited by 413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtypeLorenzo Gerratana, Grazia Arpino, Debora Basile et al.|Cancer Treatment Reviews|2018Cited by 282
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatmentMario Giuliano, Massimo Cristofanilli, Antonio Giordano et al.|Breast Cancer Research|2011Cited by 224
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to MetastasizeMario Giuliano, Meghana V. Trivedi, Anum Shaikh et al.|Cancer Research|2018Cited by 221